CTOs on the Move

ifa united I tech

www.ifa4emr.com

 
ifa united I tech is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ifa4emr.com
  • 1850 SE 17th St Ste 107
    Fort Lauderdale, FL USA 33316
  • Phone: 954.618.6277

Executives

Name Title Contact Details

Similar Companies

G.I. Windows

GIW is a clinical stage company creating a new category in healthcare designed to create less invasive surgery & reduce healthcare costs

A B Dental Trends

A B Dental Trends is a Lynden, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MPRO

MPRO is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turner Imaging Systems

Turner Imaging Systems has a long history of miniaturizing technologies for the healthcare space. Our latest innovation is the truly portable mini C-arm, the Smart-C The Turner Imaging Systems Smart-C is a mini C-arm X-ray system designed to provide physicians with realtime general fluoroscopic visualization of adult and pediatric patients. It is intended to aid physicians and surgeons during diagnostic procedures, therapeutic treatment or surgical procedures of the limbs, extremities or shoulders, including, but not limited to, orthopedics and emergency medicine. The Smart-C is intended to be used on a table or other hard, flat surface. It may also be used with the optional support stand.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.